BioNTech (BNTX) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revolution Medicines (RVMD) has outperformed BioNTech (BNTX) over the past year, gaining 293.4% versus a loss of 13.4%. Over five years, RVMD leads with a +598.0% price change compared with -62.8% for BNTX. Revolution Medicines is the larger company by market cap ($40.83 billion vs $24.33 billion), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | RVMD |
|---|---|---|
| Share price | $96.84 | $190.48 |
| Market cap | $24.33B | $40.83B |
| 1-day change | +5.19% | +1.25% |
| YTD return | -3.30% | +136.18% |
| 1-year return | -13.38% | +293.39% |
| 5-year return | -62.83% | +598.03% |
| EPS (TTM) | $-7.83 | $-8.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | — | $-1.13B |
| 52-week high | $124.00 | $224.31 |
| 52-week low | $79.52 | $47.28 |
| Distance from 52-week high | -21.90% | -15.08% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +19.57% | +35.89% |
| Average volume | 1.16M | 1.93M |
| Shares outstanding | 251.20M | 214.34M |
| Employees | 7,807 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVMD has outperformed BNTX by 306.8 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
BNTX vs RVMD FAQ
Which is bigger, BioNTech or Revolution Medicines?
Revolution Medicines (RVMD) is larger, with a market capitalization of $40.83B compared with $24.33B for BioNTech (BNTX).
Which stock has performed better over the past year, BNTX or RVMD?
RVMD returned +293.39% over the past 12 months, compared with -13.38% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Revolution Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.